Business Wire

MD-PROMETRIC

10.9.2019 15:02:09 CEST | Business Wire | Press release

Share
Professional Testing Corporation® (PTC) Selects Prometric for Global Examination Administration

Following a competitive procurement process, Professional Testing Corporation® (PTC) has selected Prometric® as their partner for the global administration of PTC client programs. Under the terms of this multi-year agreement, PTC clients will have access to Prometric’s more than 700 established, secure computer-based testing locations around the world including the most extensive network of testing locations serving professional populations in the United States and Canada.

“Prometric is pleased to have been selected by PTC to be their assessment delivery partner for the next contract period,” said Alex Paladino, Chief Revenue Officer of Prometric. “PTC has built a well-deserved reputation for customer intimacy and effective program management that has served them well over the past 25 years. Prometric will contribute to their continued success by leveraging our global scale and significant investments in technology and operations to provide testing solutions that address the evolving needs of their global certification and licensure client base.”

Prometric has been entrusted by more than 300 leading corporate, academic, and professional certification and licensure organizations to assist in the successful administration of more than 7 million computer-based, paper-based and online professional examinations annually in over 180 countries. Prometric has developed industry-leading operational practices and service capabilities that ensures that each individual will test in a secure, controlled, and consistent testing environment regardless of location. We collaborate closely with our partners from program implementation through delivery to ensure that all program requirements are fully satisfied.

“PTC looks forward to partnering with Prometric for global examination administration,” said Vicki Gremelsbacker, President of PTC. “We are confident that this strategic move will improve our candidates’ testing experiences. Prometric’s reputation for reliability and professionalism, coupled with its industry-leading security procedures and geographically diverse testing locations, will prove to be a great asset to our clients and their candidates.”

About Prometric

Prometric enables test sponsors worldwide to advance their credentialing programs through test development and delivery solutions that set the standard in quality and service excellence. Prometric offers a comprehensive and reliable approach to advising, developing, managing and delivering programs in an integrated, technology-enabled environment across the world’s most secure testing network in more than 180 countries or through the conveniences of online testing services. For more information, visit www.prometric.com or follow us on Twitter at @PrometricGlobal and www.linkedin.com/company/prometric /.

About Professional Testing Corporation

Professional Testing Corporation (PTC) is an established global leader in testing and assessment services. Founded in 1983, PTC provides a full range of certification and licensure services including job analyses, test development, test administration, accreditation and psychometric consulting, statistics and scoring, survey development and processing, and association/board management services. For more information, visit www.ptcny.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye